<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Extraction extraction-result-229 - Theorizer</title>
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/5.15.1/css/all.min.css">
    <link rel="stylesheet" href="../style.css">
</head>
<body>
    <div class="header">
        <a href="../index.html"><i class="fas fa-flask"></i> Theorizer</a>
    </div>

    <div class="content">
        <h1>Extracted Data Details for extraction-result-229</h1>

        <div class="section">
            <h2>Extracted Data (Header)</h2>
            <div class="info-section">
                <p><strong>Extraction ID:</strong> extraction-result-229</p>
                <p><strong>Extraction Schema Used (ID):</strong> <a href="../schemas/extraction-schema-9.html">extraction-schema-9</a></p>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of mechanisms, models, explanations, and supporting or refuting evidence for why specific cancers preferentially metastasize to particular organs (metastatic organotropism), including details for cancer type, primary and metastatic sites, molecular or microenvironmental factors, and any quantitative or experimental evidence.</div>
                <p><strong>Paper ID:</strong> paper-20f2236492daa5ff46b4660dc0d91a2a19bbbbba</p>
                <p><strong>Paper Title:</strong> <a href="https://www.semanticscholar.org/paper/20f2236492daa5ff46b4660dc0d91a2a19bbbbba" target="_blank">A microfluidic 3D in vitro model for specificity of breast cancer metastasis to bone.</a></p>
                <p><strong>Paper Venue:</strong> Biomaterials</p>
                <p><strong>Paper TL;DR:</strong> This study provides novel 3D in vitro quantitative data on extravasation and micrometastasis generation of breast cancer cells within a bone-like microenvironment and demonstrates the potential value of microfluidic systems to better understand cancer biology and screen for new therapeutics.</p>
                <p><strong>Cost:</strong> 0.015</p>
            </div>
        </div>

        <div class="section">
            <h2>Extracted Data (Details)</h2>
            <div class="extraction-instance-container" id="e229.0">
                <h3 class="extraction-instance">Extracted Data Instance 0 (e229.0)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of mechanisms, models, explanations, and supporting or refuting evidence for why specific cancers preferentially metastasize to particular organs (metastatic organotropism), including details for cancer type, primary and metastatic sites, molecular or microenvironmental factors, and any quantitative or experimental evidence.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>3D bone-mimicking microfluidic tri-culture model</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>A microfluidic 3D in vitro model for specificity of breast cancer metastasis to bone</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>A human-cell-based microfluidic tri-culture assay combining osteo-differentiated human bone marrow-derived MSCs embedded in type I collagen, an endothelial monolayer (HUVECs) lining a media channel, and GFP MDA-MB-231 breast cancer cells in the vessel channel to quantitatively study transendothelial migration (extravasation), migration within a bone-like matrix, and early micrometastasis formation.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>here</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>use</td>
                        </tr>
                        <tr>
                            <td><strong>cancer_type</strong></td>
                            <td>Breast cancer (MDA-MB-231)</td>
                        </tr>
                        <tr>
                            <td><strong>primary_site</strong></td>
                            <td>Breast</td>
                        </tr>
                        <tr>
                            <td><strong>preferred_metastatic_organ</strong></td>
                            <td>Bone</td>
                        </tr>
                        <tr>
                            <td><strong>proposed_mechanism</strong></td>
                            <td>Recreation of a bone-like 'soil' via osteo-differentiated hBM-MSCs that condition collagen matrix by depositing bone-matrix proteins and secreting chemokines (notably CXCL5), producing natural gradients and microenvironmental cues that enhance cancer cell adhesion to/ interaction with endothelium and promote transendothelial migration and subsequent migration/proliferation within the bone-mimicking matrix.</td>
                        </tr>
                        <tr>
                            <td><strong>supporting_evidence</strong></td>
                            <td>Tri-culture experiments comparing collagen-only vs osteo-cell conditioned collagen showed significantly higher extravasation (77.5 ± 3.7% vs 37.6 ± 7.3%) and greater migration distance into the gel (50.8 ± 6.2 μm vs 31.8 ± 5.0 μm). Endothelial monolayer integrity (VE-cadherin staining), osteogenic differentiation markers (osteocalcin, osteonectin, osteopontin) and calcium deposition (Alizarin Red) were confirmed, and cancer cells that extravasated formed Ki-67+ micrometastases over 5 days.</td>
                        </tr>
                        <tr>
                            <td><strong>counter_evidence_or_alternative_explanations</strong></td>
                            <td>No large-scale ECM structural differences were detected by confocal reflectance imaging between collagen-only and osteo-cell conditioned gels, suggesting that secreted factors rather than gross matrix remodeling mediate the effect; authors note the in vitro model cannot capture full in vivo complexity (e.g., immune cells, full bone architecture, long-term remodeling) and that longer culture might change matrix properties. Circulatory pattern effects and other chemokines could also contribute in vivo.</td>
                        </tr>
                        <tr>
                            <td><strong>key_molecules_or_factors</strong></td>
                            <td>Osteocalcin, osteonectin, osteopontin, secreted chemokines (CXCL5 emphasized), endothelial VE-cadherin (for barrier), general osteoblast-derived factors (CXCL12/SDF-1α, CX3CL1 referenced).</td>
                        </tr>
                        <tr>
                            <td><strong>experimental_model</strong></td>
                            <td>Microfluidic device with 3 media channels and 4 gel channels: 6 mg/ml type I collagen with embedded osteo-differentiated hBM-MSCs; RFP-HUVECs seeded to form endothelium in central media channel; GFP MDA-MB-231 cells introduced into the vessel channel. Conditioned assays used recombinant CXCL5 and anti-CXCR2 blocking antibody.</td>
                        </tr>
                        <tr>
                            <td><strong>quantitative_data</strong></td>
                            <td>Extravasation percentages: collagen-only 37.6 ± 7.3% (n=27-39 ROIs) vs osteo-cell conditioned 77.5 ± 3.7% (p<0.005). Migration distances: collagen-only 31.8 ± 5.0 μm vs osteo-cell conditioned 50.8 ± 6.2 μm (p<0.05). Micrometastasis: % ROIs with micrometastases 48.4% (n=31 ROIs), total micrometastases detected 38, device cell counts increased from 13.8 (day1) to 132 (day5).</td>
                        </tr>
                        <tr>
                            <td><strong>limitations_or_open_questions</strong></td>
                            <td>In vitro system lacks immune components, full bone architecture and long-term remodeling; short culture window (few days) may not recapitulate chronic changes; exact contribution of individual secreted factors beyond CXCL5 remains to be dissected; quantitative relation between in vitro chemokine concentrations and physiologic bone concentrations not fully established; effect of hemodynamics/circulatory patterns not modeled fully.</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'A microfluidic 3D in\xa0vitro model for specificity of breast cancer metastasis to bone.', 'publication_date_yy_mm': '2014-03'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e229.1">
                <h3 class="extraction-instance">Extracted Data Instance 1 (e229.1)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of mechanisms, models, explanations, and supporting or refuting evidence for why specific cancers preferentially metastasize to particular organs (metastatic organotropism), including details for cancer type, primary and metastatic sites, molecular or microenvironmental factors, and any quantitative or experimental evidence.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>CXCL5–CXCR2 axis</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Bone-secreted chemokine CXCL5 and breast cancer receptor CXCR2</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>A chemokine–receptor mechanism in which osteo-differentiated bone marrow MSCs secrete CXCL5 that binds CXCR2 on MDA-MB-231 breast cancer cells, promoting their transendothelial migration (extravasation) and chemotactic entry into a bone-like matrix; experimentally modulated by adding recombinant CXCL5 or blocking CXCR2.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>here</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>use</td>
                        </tr>
                        <tr>
                            <td><strong>cancer_type</strong></td>
                            <td>Breast cancer (MDA-MB-231)</td>
                        </tr>
                        <tr>
                            <td><strong>primary_site</strong></td>
                            <td>Breast</td>
                        </tr>
                        <tr>
                            <td><strong>preferred_metastatic_organ</strong></td>
                            <td>Bone</td>
                        </tr>
                        <tr>
                            <td><strong>proposed_mechanism</strong></td>
                            <td>CXCL5 production by osteo-differentiated hBM-MSCs generates a chemotactic gradient that attracts CXCR2-expressing breast cancer cells, facilitating firm adhesion/transendothelial migration and increased invasion into bone-like matrix; CXCL5 can activate Snail (and downstream Axl expression) linked to invasiveness (cited literature).</td>
                        </tr>
                        <tr>
                            <td><strong>supporting_evidence</strong></td>
                            <td>ELISA showed higher CXCL5 in osteo-differentiated hBM-MSC supernatants (375 ± 1.65 pg/ml) vs undifferentiated (162 ± 11.3 pg/ml). Immunofluorescence confirmed CXCR2 on MDA-MB-231. Adding recombinant CXCL5 (12 nM) to collagen-only devices increased extravasation from 37.6 ± 7.3% to 78.3 ± 9.7% and increased migration distance to 54.7 ± 5.8 μm (vs 31.8 ± 5.0 μm). Blocking CXCR2 on cancer cells (anti-CXCR2 antibody, 5 μg/ml) reduced extravasation in osteo-cell conditioned matrix from 77.5 ± 3.7% to 45.8 ± 5.4%; control IgG had no effect.</td>
                        </tr>
                        <tr>
                            <td><strong>counter_evidence_or_alternative_explanations</strong></td>
                            <td>Blocking CXCR2 did not significantly reduce the migration distance of cells that had already extravasated into osteo-cell conditioned matrix (46 ± 5.7 μm vs 50.8 ± 6.2 μm), suggesting other receptors/pathways contribute to migration within the bone matrix. Authors note other bone-derived chemokines (CXCL12/SDF-1α, CX3CL1) and paracrine/ECM factors may also promote organotropism; in vitro recombinant dosing and gradient stability may not fully mimic in vivo dynamics.</td>
                        </tr>
                        <tr>
                            <td><strong>key_molecules_or_factors</strong></td>
                            <td>CXCL5 (ENA-78), CXCR2 (receptor), Snail (transcription factor, downstream), Axl (tyrosine kinase receptor, downstream/upregulated by Snail in literature).</td>
                        </tr>
                        <tr>
                            <td><strong>experimental_model</strong></td>
                            <td>Microfluidic tri-culture assay as above; conditioned experiments included adding recombinant human CXCL5 (12 nM) to lateral media channels in collagen-only devices and incubating cancer cells with anti-CXCR2 blocking antibody (5 μg/ml) prior to seeding in osteo-cell conditioned devices; controls with IgG were used.</td>
                        </tr>
                        <tr>
                            <td><strong>quantitative_data</strong></td>
                            <td>ELISA CXCL5: osteo-differentiated hBM-MSCs 375 ± 1.65 pg/ml vs non-differentiated 162 ± 11.3 pg/ml. CXCL5 addition: extravasation 78.3 ± 9.7% (vs 37.6 ± 7.3% ctrl). CXCR2 blocking: extravasation reduced to 45.8 ± 5.4% from 77.5 ± 3.7% (p<0.005). Migration distances: CXCL5 condition 54.7 ± 5.8 μm vs collagen ctrl 31.8 ± 5.0 μm; CXCR2 blockade did not significantly change migration distance inside osteo-cell conditioned matrix (46 ± 5.7 μm vs 50.8 ± 6.2 μm).</td>
                        </tr>
                        <tr>
                            <td><strong>limitations_or_open_questions</strong></td>
                            <td>Physiologic relevance of 12 nM exogenous CXCL5 vs measured pg/ml ELISA values needs reconciliation; whether CXCL5 acts alone or in concert with other chemokines/growth factors in vivo; identity of receptors/pathways driving migration within bone beyond CXCR2; effects of stromal/immune cells absent in the model; long-term contributions to macrometastasis formation.</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'A microfluidic 3D in\xa0vitro model for specificity of breast cancer metastasis to bone.', 'publication_date_yy_mm': '2014-03'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e229.2">
                <h3 class="extraction-instance">Extracted Data Instance 2 (e229.2)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of mechanisms, models, explanations, and supporting or refuting evidence for why specific cancers preferentially metastasize to particular organs (metastatic organotropism), including details for cancer type, primary and metastatic sites, molecular or microenvironmental factors, and any quantitative or experimental evidence.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>CXCL12 / CX3CL1 (mentioned)</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>CXCL12 (SDF-1α) and CX3CL1 (fractalkine)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Chemokines previously implicated in bone tropism of breast cancer: CXCL12/SDF-1α is a well-known bone marrow chemokine implicated in tumor cell homing; CX3CL1 has been reported to mediate adhesion/arrest of breast cancer cells to the skeleton.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td></td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>cancer_type</strong></td>
                            <td>Breast cancer (general literature mention)</td>
                        </tr>
                        <tr>
                            <td><strong>primary_site</strong></td>
                            <td>Breast</td>
                        </tr>
                        <tr>
                            <td><strong>preferred_metastatic_organ</strong></td>
                            <td>Bone</td>
                        </tr>
                        <tr>
                            <td><strong>proposed_mechanism</strong></td>
                            <td>Chemokine-mediated homing/adhesion: organ-secreted chemokines create gradients or adhesion cues that attract circulating tumor cells expressing corresponding receptors (e.g., CXCR4 for CXCL12), facilitating arrest and extravasation into bone.</td>
                        </tr>
                        <tr>
                            <td><strong>supporting_evidence</strong></td>
                            <td>Mentioned as established factors in literature (cited refs in paper) but not experimentally tested in this study.</td>
                        </tr>
                        <tr>
                            <td><strong>counter_evidence_or_alternative_explanations</strong></td>
                            <td>Not explored in this paper; authors acknowledge that many factors beyond CXCL5 can promote extravasation and that the present study did not dissect all molecules.</td>
                        </tr>
                        <tr>
                            <td><strong>key_molecules_or_factors</strong></td>
                            <td>CXCL12 (SDF-1α), CX3CL1 (fractalkine) and their receptors (e.g., CXCR4, CX3CR1) as referenced in literature.</td>
                        </tr>
                        <tr>
                            <td><strong>experimental_model</strong></td>
                            <td>Not tested in this paper (literature mention only).</td>
                        </tr>
                        <tr>
                            <td><strong>quantitative_data</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>limitations_or_open_questions</strong></td>
                            <td>Relative contributions of CXCL12/CX3CL1 vs CXCL5 in human bone metastasis not addressed in this work; need for direct comparative experiments.</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'A microfluidic 3D in\xa0vitro model for specificity of breast cancer metastasis to bone.', 'publication_date_yy_mm': '2014-03'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e229.3">
                <h3 class="extraction-instance">Extracted Data Instance 3 (e229.3)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of mechanisms, models, explanations, and supporting or refuting evidence for why specific cancers preferentially metastasize to particular organs (metastatic organotropism), including details for cancer type, primary and metastatic sites, molecular or microenvironmental factors, and any quantitative or experimental evidence.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>Seed-and-soil hypothesis</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Seed and soil hypothesis</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Classic explanatory framework proposing that metastatic organ specificity arises from interactions between properties of disseminating tumor cells ('seed') and permissive features of target organs ('soil'), including stromal cells, ECM and secreted factors.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td></td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>cancer_type</strong></td>
                            <td>General (breast cancer used as primary example in this paper)</td>
                        </tr>
                        <tr>
                            <td><strong>primary_site</strong></td>
                            <td>Breast (context of discussion)</td>
                        </tr>
                        <tr>
                            <td><strong>preferred_metastatic_organ</strong></td>
                            <td>Bone (as example of receptive 'soil' for breast cancer)</td>
                        </tr>
                        <tr>
                            <td><strong>proposed_mechanism</strong></td>
                            <td>Organotropism arises from selective compatibility between tumor cell molecular programs and organ-specific microenvironmental cues (chemokines, ECM proteins, resident cells) that favor survival, adhesion, extravasation and outgrowth.</td>
                        </tr>
                        <tr>
                            <td><strong>supporting_evidence</strong></td>
                            <td>Cited historically and used to motivate organ-specific microenvironment modeling in this paper; the study operationalizes testing of 'seed-and-soil' by showing osteo-conditioned matrix increases extravasation/proliferation of MDA-MB-231 cells.</td>
                        </tr>
                        <tr>
                            <td><strong>counter_evidence_or_alternative_explanations</strong></td>
                            <td>Circulatory patterns and mechanical trapping also play roles; authors note both hemodynamics and cell–microenvironment cross-talk contribute and are not mutually exclusive.</td>
                        </tr>
                        <tr>
                            <td><strong>key_molecules_or_factors</strong></td>
                            <td>General concept — chemokines (CXCL5, CXCL12), ECM proteins (osteocalcin, osteonectin, osteopontin), endothelial adhesion molecules.</td>
                        </tr>
                        <tr>
                            <td><strong>experimental_model</strong></td>
                            <td>Conceptual framework motivating the microfluidic bone-mimicking tri-culture model used in this paper.</td>
                        </tr>
                        <tr>
                            <td><strong>quantitative_data</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>limitations_or_open_questions</strong></td>
                            <td>How to quantitatively integrate hemodynamic, cellular and molecular contributions to organotropism; how generalizable are findings across tumor subtypes and patient-specific bone niches.</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'A microfluidic 3D in\xa0vitro model for specificity of breast cancer metastasis to bone.', 'publication_date_yy_mm': '2014-03'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e229.4">
                <h3 class="extraction-instance">Extracted Data Instance 4 (e229.4)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of mechanisms, models, explanations, and supporting or refuting evidence for why specific cancers preferentially metastasize to particular organs (metastatic organotropism), including details for cancer type, primary and metastatic sites, molecular or microenvironmental factors, and any quantitative or experimental evidence.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>Snail → Axl pathway (literature-cited)</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Snail activation leading to Axl upregulation (EMT-linked pathway)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>A proposed molecular route whereby CXCL5 can activate Snail (a transcription factor linked to invasiveness/EMT), which can in turn upregulate the receptor tyrosine kinase Axl; Axl has been implicated in promoting extravasation and metastatic potential in breast cancer (cited literature).</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td></td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>cancer_type</strong></td>
                            <td>Breast cancer (contextual literature mention)</td>
                        </tr>
                        <tr>
                            <td><strong>primary_site</strong></td>
                            <td>Breast</td>
                        </tr>
                        <tr>
                            <td><strong>preferred_metastatic_organ</strong></td>
                            <td>Bone (implicated in extravasation/migration processes)</td>
                        </tr>
                        <tr>
                            <td><strong>proposed_mechanism</strong></td>
                            <td>CXCL5 → Snail activation → upregulation of Axl → enhanced invasiveness/extravasation capability of tumor cells.</td>
                        </tr>
                        <tr>
                            <td><strong>supporting_evidence</strong></td>
                            <td>Paper cites prior studies linking CXCL5 to Snail activation and Snail to Axl upregulation and Axl to extravasation, but this pathway was not directly tested in the present experiments.</td>
                        </tr>
                        <tr>
                            <td><strong>counter_evidence_or_alternative_explanations</strong></td>
                            <td>Not experimentally evaluated in this study; blocking CXCR2 reduced extravasation but did not fully abrogate migration within the osteo-cell conditioned matrix, implying other downstream effectors or parallel pathways may act.</td>
                        </tr>
                        <tr>
                            <td><strong>key_molecules_or_factors</strong></td>
                            <td>Snail (transcription factor), Axl (tyrosine kinase receptor), CXCL5 (upstream ligand).</td>
                        </tr>
                        <tr>
                            <td><strong>experimental_model</strong></td>
                            <td>Mentioned via literature citations; not experimentally manipulated directly in this paper.</td>
                        </tr>
                        <tr>
                            <td><strong>quantitative_data</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>limitations_or_open_questions</strong></td>
                            <td>Direct causal links and temporal sequence of Snail and Axl induction by osteoblast-derived CXCL5 in human breast cancer extravasation remain to be experimentally validated in organ-specific models.</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'A microfluidic 3D in\xa0vitro model for specificity of breast cancer metastasis to bone.', 'publication_date_yy_mm': '2014-03'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
        </div>

        <div class="section">
            <h2>Potentially Relevant New Papers (mentioned by this paper)</h2>
            <ol>
                <li>Mesenchymal stem cells promote mammary cancer cell migration in vitro via the CXCR2 receptor <em>(Rating: 2)</em></li>
                <li>Breast tumor-associated osteoblast-derived CXCL5 increases cancer progression by ERK/MSK1/Elk-1/Snail signaling pathway <em>(Rating: 2)</em></li>
                <li>Involvement of chemokine receptors in breast cancer metastasis <em>(Rating: 2)</em></li>
                <li>The chemokine receptor CX(3)CR1 is directly involved in the arrest of breast cancer cells to the skeleton <em>(Rating: 2)</em></li>
                <li>In vitro model of tumor cell extravasation <em>(Rating: 2)</em></li>
                <li>The bone microenvironment in metastasis; what is special about bone? <em>(Rating: 2)</em></li>
            </ol>
        </div>

        </div>

    </div>
</body>
</html>